Sutro Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference
Sutro Biopharma (NASDAQ: STRO) announced that Jane Chung, Chief Executive Officer, will present at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sutro Biopharma (NASDAQ: STRO) announced that Jane Chung, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026 at 11:15 AM PT / 2:15 PM ET in San Francisco.
A live webcast will be accessible via the Events & Presentations page of the Investor Relations section at www.sutrobio.com. An archived replay will be available for at least 30 days after the event.
Key Figures
- Conference edition
- 44th Annual
- J.P. Morgan Healthcare Conference
- Presentation date
- January 15, 2026
- J.P. Morgan Healthcare Conference
- Presentation time PT
- 11:15 AM PT
- Company presentation slot
- Presentation time ET
- 2:15 PM ET
- Company presentation slot
- Replay availability
- at least 30 days
- Archived webcast on Investor Relations site
Historical Context
-
Nasdaq confirmed Sutro regained minimum bid price listing compliance.
-
Inducement stock options and RSUs granted to new employees.
-
First cohort dosed in Phase 1 trial of STRO-004 in solid tumors.
-
1-for-10 reverse split implemented to address Nasdaq bid price issue.
-
Virtual R&D Day highlighting next‑generation ADC platform and pipeline.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
antibody drug conjugates medical
adcs medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Jane Chung, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 11:15 AM PT / 2:15 PM ET in San Francisco, CA.
A live webcast of the presentation will be accessible through the Events & Presentations page of the Investor Relations section of the Company’s website at www.sutrobio.com. An archived replay will be available for at least 30 days after the event.
About Sutro Biopharma
Sutro Biopharma, Inc. is advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro’s cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine what’s possible in cancer therapy. The Company’s pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies. For more information, follow Sutro on social media @Sutrobio or visit www.sutrobio.com.
Investor Contact:
Emily White
Sutro Biopharma
(650) 823-7681
ewhite@sutrobio.com
Media Contact:
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.